FY2029 Earnings Forecast for Savara Issued By HC Wainwright

Savara Inc (NASDAQ:SVRA) – Stock analysts at HC Wainwright lowered their FY2029 earnings per share (EPS) estimates for shares of Savara in a research note issued to investors on Wednesday, May 14th. HC Wainwright analyst A. Fein now anticipates that the company will earn $0.14 per share for the year, down from their prior estimate of $0.17. HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.45) per share.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.12).

Savara Trading Up 4.0%

NASDAQ:SVRA opened at $3.11 on Thursday. The stock’s 50 day moving average price is $2.93 and its 200 day moving average price is $3.03. The company has a market capitalization of $537.25 million, a PE ratio of -7.23 and a beta of 0.44. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara has a 52-week low of $2.26 and a 52-week high of $5.11.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in SVRA. Frazier Life Sciences Management L.P. grew its stake in Savara by 32.4% during the 1st quarter. Frazier Life Sciences Management L.P. now owns 11,462,301 shares of the company’s stock worth $31,751,000 after buying an additional 2,801,922 shares during the last quarter. Vestal Point Capital LP grew its stake in Savara by 33.2% during the 4th quarter. Vestal Point Capital LP now owns 10,775,000 shares of the company’s stock worth $33,079,000 after buying an additional 2,685,000 shares during the last quarter. Rosalind Advisors Inc. purchased a new position in Savara during the 4th quarter worth approximately $8,151,000. Nantahala Capital Management LLC grew its stake in shares of Savara by 45.2% in the 4th quarter. Nantahala Capital Management LLC now owns 7,525,259 shares of the company’s stock valued at $23,103,000 after purchasing an additional 2,344,308 shares during the last quarter. Finally, Emerald Advisers LLC purchased a new position in shares of Savara in the 4th quarter valued at approximately $7,161,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.